Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and colleagues at the University of Virginia in Charlottesville have succeeded in imaging, in unprecedented detail, the virus that causes influenza.
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, began shipping influenza vaccine (Fluzone, Influenza Virus Vaccine) to the U.S. market for the 2006-2007 season.
Scientists in the United States have developed a new technology that reduces the time it takes to achieve a detailed diagnosis of avian flu, from one week or more down to less than 12 hours.
Scientists from the University of Colorado at Boulder and the Centers for Disease Control and Prevention (CDC) have developed a microchip-based test that may allow more labs to diagnose influenza infections and learn more about the viruses causing illness.
Study provides first assessment of the risk of an H5N1 pandemic strain emerging from the combining of avian and human influenza viruses.
A team of scientists at the U.S. Centers for Disease Control and Prevention (CDC) have developed a new research method that may help identify the types of genetic changes that would be necessary for the avian influenza virus (H5N1) to be more easily transmitted among people.
Health authorities in the U.S. are advising doctors to stop using two drugs to treat this winters influenza because it has become evident that the most common strain has become resistant to the drugs and they are unlikely to work.
A new study has shown that flu killed more U.S. children than chicken pox, whooping cough, and measles combined in the 2003-2004 flu season.
A novel "Flu Chip" developed at the University of Colorado at Boulder that can determine the genetic signatures of specific influenza strains from patient samples within hours may help world health officials combat coming epidemics and pandemics.
In the first large-scale effort of its kind, researchers have determined the full genetic sequence of more than 200 distinct strains of human influenza virus.
On the eve of the 2005-06 flu season, scientists at The Institute for Genomic Research (TIGR) have captured influenza evolution in action. In a study published in this week's journal Nature, the researchers report the first large-scale project to sequence the influenza virus.
Multiple strains of the flu virus, circulating in a population at the same time, can reshuffle their genes and create a new virus, one capable of infecting many more people, according to a new study in the open-access journal PLoS Biology.
New Zealanders who were immunised against influenza last year are likely to have some protection against the current influenza viruses hitting schools around the country.
The HPA Influenza Pandemic Contingency Plan outlines the Health Protection Agency’s plan for responding to an influenza pandemic. It replaces the Public Health Laboratory Service Pandemic Influenza Plan of July 2001.
Influenza (or as it is commonly known, the flu) is a contagious disease caused by an RNA virus of the orthomyxoviridae family (The orthomyxoviridae is a family of RNA viruses which infect vertebrate).
Now the United Nations health agency is investigating reports that bird flu, which experts say could mutate into a potentially deadly human pandemic under certain conditions, has now jumped the species barrier to infect cats.
Results of a small study from Japan in this week’s issue of THE LANCET suggest that the emergence of influenza viruses which are resistant to a widely used influenza drug may be more common than previously thought.
Considering the widespread nature of the current H5N1 outbreak in Asia and the capability of influenza viruses to jump the species barriers, it is inevitable that H5N1 virus will be detected in some pigs.
Aventis began to ship its influenza vaccine (Fluzone(R), Influenza Virus Vaccine) today, meeting the company's goal to provide Fluzone vaccine to customers to allow health-care providers to plan successful immunization programs for the upcoming influenza season.
PRB Pharmaceuticals and Lee's Pharmaceuticals have announced the discovery that PRB'S patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu (H3N2) infections in vitro.